AlphAIAlphAI — Financial news for AI agents
seekingalpha.com$AMRX

Amneal raises 2026 forecast but lowers operating cash flow outlook (AMRX:NASDAQ)

Amneal Pharmaceuticals reported Q3 Non-GAAP EPS of $0.26, exceeding estimates by $0.02. Revenue rose 9.9% year-over-year to $863M, also beating expectations. The company raised its FY2026 adjusted EPS forecast to $1.04–$1.08 and net revenue guidance to $3.15B–$3.25B, though revenue guidance was slightly below consensus.

Original reporting
seekingalpha.com
Published Nov 3, 2026, 11:12 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 11:16 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$AMRX
Bullish
high confidence
Mentioned
$AMRX
Relevance
8/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$AMRXBullishHigh
01

Why it matters

The beat on EPS and revenue guidance may trigger buying interest and short covering.

02

Market read

First‑report earnings guidance that exceeds consensus, offering a clear trading catalyst.

03

What to watch

Potential headwinds from drug pipeline delays or regulatory hurdles not reflected in guidance.

Relevance 8/10Novelty 9/10Timing: after-hours today

Background

Amneal Pharmaceuticals released its Q3 results and updated FY2026 guidance.

Company-level read

Ticker impact

$AMRXBullishHigh confidence
Context

Amneal raised FY2026 EPS guidance to $1.04‑$1.08 and revenue guidance to $3.15B‑$3.25B, beating consensus.

Expected impact

likely upward pressure as market prices in the stronger guidance

Evidence & confidence

Guidance exceeds consensus estimates, which typically drives a positive price reaction.

Market effects

Sector

Improves outlook for specialty pharma sector as earnings beat may lift peers.

Regional

U.S. biotech stocks may see modest gains.

Global

Limited to investors focused on U.S. pharma; no broad macro effect.

Counterpoint

What could challenge this read

If guidance is overly optimistic, the stock could face a pull‑back on earnings release.

Key entities

  • company
    Amneal Pharmaceuticals

    U.S. specialty pharmaceutical company.

Read at source← All news

StoryAmneal Pharmaceuticals raises 2026 revenue and earnings guidance after Q3 2026 results

Also covered by

4 outlets

Related articles

$AMRXHighAI 8/10

Amneal Earnings Call Signals Strong Growth Ahead

Amneal Pharmaceuticals (AMRX) reported Q3 revenue of $863M, up 10% YoY, with adjusted EBITDA rising 30% to $207M and adjusted EPS increasing 53% to $0.26. The company raised its 2026 revenue outlook to $3.15B-$3.25B and adjusted EBITDA guidance to $800M-$815M. Growth was driven by specialty brands, the Kashiv acquisition, and biosimilar platforms, though management noted pressure from AvKARE and temporarily higher leverage.

tipranks.com
$AMRXMed

Piper Sandler reiterates Amneal stock rating on earnings beat

Piper Sandler maintained an Overweight rating and $21.00 price target for Amneal Pharmaceuticals (NYSE: AMRX) after its Q3 earnings beat estimates. Amneal reported $0.26 EPS on $862.7M revenue, raising 2026 revenue guidance to $3.15B-$3.25B. Shares are up 78% year-over-year, trading near a 52-week high. Piper Sandler expects steady EBITDA growth and improved leverage ratios.

investing.com
$AMRXMedAI 8/10

What Amneal Pharmaceuticals (AMRX) Said on Its Q3 Earnings Call

Amneal Pharmaceuticals (AMRX) reported Q3 revenue growth in affordable medicines (19% to $547M) and specialty products (20% to $150M), while AvKARE revenue declined 17% to $165M. Adjusted gross margin increased to 43.2%. The company launched lanreotide, targeting 30-40% market share, and expects significant biosimilar growth. Specialty brands like CREXONT and BREKIYA showed strong performance. Amneal plans manufacturing expansions and aims to reduce leverage below 3x EBITDA by 2028.

finance.yahoo.com